<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758611</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-0001</org_study_id>
    <nct_id>NCT04758611</nct_id>
  </id_info>
  <brief_title>The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt)</brief_title>
  <acronym>ETCHES I</acronym>
  <official_title>Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc eShunt™ System in the Treatment of Communicating Hydrocephalus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CereVasc Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AlvaMed, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioscience Consulting, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simplified Clinical Data Systems, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CereVasc Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The eShunt™ System is a minimally invasive method of treating communicating hydrocephalus.&#xD;
      The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a&#xD;
      permanent implant deployed in a minimally invasive, neuro-interventional procedure. The&#xD;
      eShunt Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial&#xD;
      subarachnoid space (SAS) into the venous system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, open label, single-arm pilot study of the eShunt&#xD;
      System. The study population consists of patients with post-aneurysmal subarachnoid&#xD;
      hemorrhage (SAH) treated for increased intracranial pressure (ICP) resulting in symptomatic&#xD;
      hydrocephalus using an external ventricular drain (EVD) to facilitate CSF drainage and who&#xD;
      cannot be &quot;weaned&quot; from the EVD seven or more days following the hemorrhagic event.&#xD;
&#xD;
      The study will be performed a single site with up to 30 subjects who meet the inclusion and&#xD;
      exclusion criteria for the study. Subjects will be evaluated every 30 days for the first 90&#xD;
      days following eShunt Implant deployment with standard neurological evaluation appropriate&#xD;
      for patients with communicating hydrocephalus. In addition, follow-up will occur at 180 days,&#xD;
      12 and 24 months post-operatively and will include imaging in addition to the standard&#xD;
      neurological evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-center, open-label, single-arm pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in intracranial pressure (ICP)</measure>
    <time_frame>36-48 hours following eShunt Implant deployment</time_frame>
    <description>At 36-48 hours following eShunt Implant deployment and with EVD remaining clamped, an ICP assessment that demonstrates: 1) ICP below 20 cmH2O as measured by the EVD with no periods longer than 15 minutes above 20 cmH2O; and 2) No episodes of ICP, measured by EVD, above 25 cmH2O with associated subject symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects requiring conversion to conventional CSF shunt</measure>
    <time_frame>24 months following eShunt Implant deployment</time_frame>
    <description>Evaluate the need for CSF diversion by conventional CSF shunt insertion within the 24 months following eShunt Implant deployment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormal laboratory test results</measure>
    <time_frame>24 months following eShunt Implant deployment</time_frame>
    <description>Clinically significant changes from baseline laboratory test results will be summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline MRI imaging</measure>
    <time_frame>24 months following eShunt Implant deployment</time_frame>
    <description>Clinically significant changes from baseline MRI images will be summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline CT imaging</measure>
    <time_frame>24 months following eShunt Implant deployment</time_frame>
    <description>Clinically significant changes from baseline CT images will be summarized</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Endpoint: serious adverse events (SAEs)</measure>
    <time_frame>24 months following eShunt Implant deployment</time_frame>
    <description>Evaluate for any device or procedure related serious adverse events (SAEs)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hydrocephalus, Communicating</condition>
  <condition>Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Treatment Arm receives the eShunt implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eShunt™ Implant</intervention_name>
    <description>The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>eShunt™</other_name>
    <other_name>eShunt™ System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18&#xD;
&#xD;
          2. Subject provides Informed Consent (IC)&#xD;
&#xD;
          3. Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place for &gt; 7 days with&#xD;
             the need for a permanent CSF shunt determined through a failed EVD clamping trial&#xD;
             defined as:&#xD;
&#xD;
               1. Post-clamping ICP of &gt; 20 cmH2O for 15 min, or&#xD;
&#xD;
               2. Post-clamping ICP &gt; 25 cmH2O for &lt; 15 min with patient intolerance to EVD&#xD;
                  clamping&#xD;
&#xD;
          4. Clinical signs and symptoms of communicating hydrocephalus&#xD;
&#xD;
          5. Neurologically stable without evidence of severe vasospasm&#xD;
&#xD;
          6. Pre-procedure MRI with gadolinium confirmation of IPS (inferior petrosal sinus) and&#xD;
             CPA (cerebellopontine angle) cistern anatomy suitable for eShunt Implant deployment as&#xD;
             confirmed by SSC (subject screening committee)&#xD;
&#xD;
          7. Pre-procedure CT confirmation of no obstruction preventing CPA cistern access at&#xD;
             target implant site (e.g., petrous bone) as confirmed by SSC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is in a state of unconsciousness or is unable to understand the information&#xD;
             provided in the Informed Consent Form for this study&#xD;
&#xD;
          2. Indication of obstructive hydrocephalus&#xD;
&#xD;
          3. Presence of gross blood in CSF from EVD&#xD;
&#xD;
          4. Pregnant&#xD;
&#xD;
          5. Unwilling or unable to comply with follow up requirements&#xD;
&#xD;
          6. Active systemic infection or infection detected in CSF&#xD;
&#xD;
          7. Life expectancy &lt; 1 year&#xD;
&#xD;
          8. Hypersensitivity or contraindication to heparin or radiographic contrast agents which&#xD;
             cannot be adequately pre-medicated, desensitized or where no alternative is available&#xD;
&#xD;
          9. Occlusion or stenosis of the internal jugular vein&#xD;
&#xD;
         10. Venous distension in the neck on physical exam&#xD;
&#xD;
         11. Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram&#xD;
&#xD;
         12. History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases&#xD;
             of emergency&#xD;
&#xD;
         13. Clearly antecedent stroke unrelated to post-aneurysmal SAH&#xD;
&#xD;
         14. Patient is currently participating in another investigational drug or device trial&#xD;
             that could conflict with study data collection or follow-up&#xD;
&#xD;
         15. Other medical illnesses that may cause the patient to be non-compliant with the&#xD;
             protocol or confound data interpretation as determined by the study Investigator&#xD;
&#xD;
         16. Presence of a deep vein thrombosis&#xD;
&#xD;
         17. International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results&#xD;
             outside of normal range (INR 0.8-1.4; PTT 25-35 secs.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro M Lylyk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Sagrada Familia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janelle Arrambide</last_name>
    <phone>5129947597</phone>
    <email>clinicaltrials@cerevasc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DJ Cass</last_name>
    <email>clinicaltrials@cerevasc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica La Sagrada Familia</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad A. De Buenos Aires</state>
        <zip>C1426B</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Toranzo</last_name>
      <email>ctoranzo@lylyk.com.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9.</citation>
    <PMID>30626626</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eShunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocephalus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

